- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Johnson & Johnson(JNJ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for JNJ
11/13/2026: JNJ (5-star) is a STRONG-BUY. BUY for 5 days. Simulated Profits (1.29%). Updated daily EoD!
Johnson & Johnson is a premier global healthcare enterprise operating through innovative medicine and medtech segments. The company's core strengths lie in its blockbuster pharmaceutical portfolio, strong research capabilities, and elite balance sheet supporting consistent dividend growth. Its primary growth opportunity stems from pipeline expansion in oncology and strategic acquisitions in medical technology. Key risks include impending patent expirations, pricing pressures, and litigation uncertainties. The stock suits conservative and income-focused investors seeking defensive stability, with ongoing attention required on pipeline execution and patent cliff offsets.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | J&J offers steady mid-single-digit growth rather than high-octane hyper-growth. |
| Momentum investor | Strong fit while signal remains positive | Momentum fit is conditional on a positive Upturn signal driven by strong pipeline or medtech execution. |
| Value investor | Strong fit | The stock often trades at reasonable valuation multiples relative to its stable healthcare earnings and cash flows. |
| Dividend investor | Strong fit | As a Dividend King with decades of consecutive payout increases, it is a premier option for income-seeking investors. |
| Low-risk investor | Strong fit | Its defensive business model, low economic sensitivity, and AAA-rated financial profile suit conservative portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | Healthcare demand is defensive, resulting in lower price volatility compared to cyclical sectors. |
| Valuation risk | Medium | Valuation remains reasonable, but broad market shifts can influence healthcare sector pricing multiples. |
| Competition risk (Pharmaceutical and MedTech competition) | Medium / high | Intense rivalry from peers in oncology, immunology, and medical devices threatens market share and pricing. |
| Business quality | Strong | The company boasts elite franchise quality, high margins, and world-class operational scale. |
| Dividend income | Strong | Reliable cash flow generation secures its elite dividend growth record. |
| Execution risk | Medium | Successful clinical trials and smooth integration of large MedTech acquisitions are vital to sustain growth. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 687.89B USD | Price to earnings Ratio 43.36 | 1Y Target Price 279.41 |
Price to earnings Ratio 43.36 | 1Y Target Price 279.41 | ||
Volume (30-day avg) 7.7M shares | Beta 0.2 | 52 Weeks Range 191.58 - 288.11 | Updated Date 11/15/2026 |
52 Weeks Range 191.58 - 288.11 | Updated Date 11/15/2026 | ||
Dividends yield (FY) 1.86% | Basic EPS (TTM) 6.59 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Drug Manufacturers - General
- BUY participation
- 77.8%
- Active BUY / eligible
- 7 / 9
- 30-Day BUY Count Change
- +4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 63% | Avg. Invested days 64 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Innovative Medicine (Pharmaceuticals) | Prescription drugs and biologics targeting oncology, immunology, neuroscience, and cardiovascular diseases. | This is J&J's primary profit engine, driven by blockbuster patented therapies. |
| MedTech | Surgical instruments, orthopedics, vision care, and cardiovascular intervention devices. | Provides steady, recurring hospital-based revenue tied to surgical procedures globally. |
| Geographic Exposure | Global commercial sales spanning North America, Europe, Asia-Pacific, and Latin America. | International diversification cushions against regional economic downturns. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 43.36 | Forward PE 24.1 | Enterprise Value 715.31B | Price to Sales(TTM) 6.92 |
Enterprise Value 715.31B | Price to Sales(TTM) 6.92 | ||
Enterprise Value to Revenue 7.2 | Enterprise Value to EBITDA 26.68 | Shares Outstanding 2.41B | Shares Floating 2.40B |
Shares Outstanding 2.41B | Shares Floating 2.40B | ||
Percent Insiders 0.22 | Percent Institutions 77.06 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

